JP2014512333A5 - - Google Patents

Download PDF

Info

Publication number
JP2014512333A5
JP2014512333A5 JP2013549539A JP2013549539A JP2014512333A5 JP 2014512333 A5 JP2014512333 A5 JP 2014512333A5 JP 2013549539 A JP2013549539 A JP 2013549539A JP 2013549539 A JP2013549539 A JP 2013549539A JP 2014512333 A5 JP2014512333 A5 JP 2014512333A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
metformin
composition according
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013549539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014512333A (ja
JP5911514B2 (ja
Filing date
Publication date
Priority claimed from US13/348,265 external-priority patent/US20120178813A1/en
Application filed filed Critical
Publication of JP2014512333A publication Critical patent/JP2014512333A/ja
Publication of JP2014512333A5 publication Critical patent/JP2014512333A5/ja
Application granted granted Critical
Publication of JP5911514B2 publication Critical patent/JP5911514B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013549539A 2011-01-12 2012-01-12 脂質低下抗糖尿病薬 Expired - Fee Related JP5911514B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161461113P 2011-01-12 2011-01-12
US61/461,113 2011-01-12
US13/348,265 2012-01-11
US13/348,265 US20120178813A1 (en) 2011-01-12 2012-01-11 Lipid-lowering antidiabetic agent
PCT/US2012/021070 WO2012097144A1 (en) 2011-01-12 2012-01-12 Lipid-lowering antidiabetic agent

Publications (3)

Publication Number Publication Date
JP2014512333A JP2014512333A (ja) 2014-05-22
JP2014512333A5 true JP2014512333A5 (enExample) 2015-03-12
JP5911514B2 JP5911514B2 (ja) 2016-04-27

Family

ID=46455756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013549539A Expired - Fee Related JP5911514B2 (ja) 2011-01-12 2012-01-12 脂質低下抗糖尿病薬

Country Status (12)

Country Link
US (4) US20120178813A1 (enExample)
EP (1) EP2663186A4 (enExample)
JP (1) JP5911514B2 (enExample)
KR (1) KR20140092228A (enExample)
CN (1) CN103533833B (enExample)
AU (1) AU2012205547B2 (enExample)
BR (1) BR112013017845A2 (enExample)
CA (1) CA2824192A1 (enExample)
EA (1) EA201391028A1 (enExample)
IL (1) IL227346A0 (enExample)
MX (1) MX2013008131A (enExample)
WO (1) WO2012097144A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
MX2015000408A (es) * 2012-07-10 2015-07-14 Thetis Pharmaceuticals Llc Forma de triple sal de metformina.
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2014080307A2 (en) * 2012-11-21 2014-05-30 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014195810A2 (en) * 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
AU2014276346A1 (en) * 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
WO2015022613A1 (en) * 2013-08-11 2015-02-19 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
EP3140316A1 (en) * 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
EP3157936B1 (en) 2014-06-18 2018-10-17 Thetis Pharmaceuticals LLC Mineral amino-acid complexes of active agents
WO2016132186A1 (en) * 2015-02-20 2016-08-25 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
US9371276B1 (en) * 2015-03-21 2016-06-21 Mohan Murali Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
WO2019008101A1 (en) 2017-07-06 2019-01-10 Evonik Technochemie Gmbh ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS
CN111032032B (zh) 2017-08-15 2024-01-02 赢创运营有限公司 具有高活性成分含量的ω-3脂肪酸氨基酸盐的片剂
WO2019120111A1 (zh) * 2017-12-18 2019-06-27 镇学初 二甲双胍盐在治疗脑梗死中的用途
US20220287345A1 (en) 2019-08-08 2022-09-15 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives
US20220280387A1 (en) 2019-08-08 2022-09-08 Evonik Operations Gmbh Down streaming process for the production of polyunsaturated fatty acid salts
CN113105367B (zh) 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN115192625A (zh) * 2022-06-30 2022-10-18 山东海赜生物科技有限公司 一种口服组合物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
KR100784752B1 (ko) 2000-02-04 2007-12-13 다케다 야쿠힌 고교 가부시키가이샤 안정한 에멀젼 조성물
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
FR2818906B1 (fr) * 2000-12-29 2004-04-02 Dospharma Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
DE10102050A1 (de) 2001-01-17 2002-07-18 Basf Ag Zubereitung zur Verbesserung der Nahrungsverwertung
JP4220247B2 (ja) 2001-03-29 2009-02-04 ビーエーエスエフ ソシエタス・ヨーロピア 共役不飽和グリセリド混合物及びその製造方法
EP1429602B1 (en) 2001-08-31 2009-12-16 Rutgers, The State University Of New Jersey Methods for treating disorders using plant extracts
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US20030220301A1 (en) * 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
EP2384750A1 (en) * 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
PL377614A1 (pl) * 2003-03-18 2006-02-06 Novartis Ag Kompozycje zawierające kwasy tłuszczowe i aminokwasy
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20080045559A1 (en) 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
WO2005041926A1 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
CA2554617A1 (en) 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
US20060003976A1 (en) 2004-06-04 2006-01-05 Yuehua Zhang Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
JP5491697B2 (ja) * 2004-10-15 2014-05-14 フォトンズ コーポレイション リミテッド 高レベルオメガ−3および低レベル飽和脂肪酸を含む組成物
CN101094683A (zh) 2004-10-29 2007-12-26 J·坎贝尔-托夫特 从催吐萝芙木和酸橙中分离的抗糖尿病提取物及其使用方法
EP1898922A4 (en) 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
AU2007213506A1 (en) * 2006-02-07 2007-08-16 Universitetet I Oslo Omega 3
JP2009526747A (ja) 2006-02-16 2009-07-23 武田薬品工業株式会社 環状アミン化合物および高血圧の予防・治療のための用途
US20090047340A1 (en) 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
US7973073B2 (en) 2006-06-16 2011-07-05 Indigene Pharmaceuticals, Inc. Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
KR101438177B1 (ko) 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
WO2008053340A1 (en) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
US20100105773A1 (en) * 2006-11-09 2010-04-29 The Children's Medical Center Corporation Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
WO2008093984A1 (en) * 2007-01-29 2008-08-07 Hanall Pharmaceutical Company. Ltd N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20090227560A1 (en) 2007-04-27 2009-09-10 Takanobu Kuroita Substituted imidazole compound and use thereof
CL2008001163A1 (es) 2007-04-27 2008-12-19 Takeda Pharmaceutical Compuestos derivados de 1h-imidazo-4-il(piperazibn) metanona, inhibidores de renina superior, composicion farmaceutica que comprende a dichos compuestos; y uso de los compuestos para el tratamiento o prevencion de la hipertension.
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
WO2009038396A2 (en) * 2007-09-21 2009-03-26 Hanall Pharmaceutical Company. Ltd N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
JP5441705B2 (ja) 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
JP2011519915A (ja) 2008-05-05 2011-07-14 オラムド エルティーディー. エクセナチドの経口投与用の方法および組成物
PE20110067A1 (es) 2008-06-19 2011-02-18 Takeda Pharmaceutical Derivados de piperidina como inhibidores de renina
MX2011011517A (es) * 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
US20110052678A1 (en) 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP2014512333A5 (enExample)
JP2015523382A5 (enExample)
Ali et al. Anti-leishmanial activity of heteroleptic organometallic Sb (V) compounds
Köppen et al. Solvent-dependent formation of three new Bi-metal–organic frameworks using a tetracarboxylic acid
JP2014524442A5 (enExample)
JP2012067131A5 (enExample)
JP6160621B2 (ja) ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物
JP2013518107A5 (enExample)
JP2012512197A5 (enExample)
JP2011037841A5 (enExample)
Kniazeva et al. Nuclearity control in calix [4] arene-based zinc (ii) coordination complexes
JP2015516419A5 (enExample)
RU2008152751A (ru) Соли тримебутина и n-десметилтримебутина
Božić et al. Synthesis, characterization and antiproliferative activity of transition metal complexes with 3-(4, 5-diphenyl-1, 3-oxazol-2-yl) propanoic acid (oxaprozin)
RU2019138773A (ru) Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций
RU2016134404A (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА α МОНОБЕНЗОАТА СОЕДИНЕНИЯ А, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЕ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
PE20131327A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen
RU2017142996A (ru) Натриевая соль ингибитора транспортера мочевой кислоты и его кристаллическая форма
JP2014518280A5 (enExample)
JP2010540440A5 (enExample)
JP2018509421A5 (enExample)
WO2014008379A3 (en) Diamine and meglumine salt forms of fatty acids
JP2014520066A5 (enExample)
CN105199711B (zh) 咔唑衍生物作为摩擦发光材料在制作压感发光体或压力传感器中的应用
CO6380006A1 (es) Proceso para producción de magnetita sintética de alta pureza por oxidación a partir de residuos metálicos y aparato para producirla